

Siemens Healthineers on Track to Meet Fiscal Year 2024 Targets After Second Quarter



Siemens Healthineers AG announces its results for the second quarter of fiscal year 2024 ended March 31, 2024.

Q2 Fiscal Year 2024

- · Good equipment book-to-bill ratio of 1.08
- Comparable revenue growth of 3.0% against a very good prior-year quarter (excluding rapid COVID-19 antigen tests, growth of 11.7%)
- Imaging comparable revenue growth of 2.6% against significant growth in the prior-year quarter; adjusted EBIT margin of 20.2%
- Diagnostics comparable revenue growth of 3.7% (excluding rapid COVID-19 antigen tests 4.1%); adjusted EBIT margin 4.1%, clearly above the prior-year quarter
- Varian comparable revenue down slightly by 2.1% against the excellent prior-year quarter (growth of 27%); clear improvement in adjusted EBIT margin to 16.4%
- Advanced Therapies comparable revenue growth of 8.0% against very strong growth in the prior-year quarter; adjusted EBIT margin of 16.2%
- Overall adjusted EBIT margin of 15.1%
- Adjusted basic earnings per share of €0.55

Outlook for Fiscal Year 2024

We confirm our expectation of comparable revenue growth of between 4.5% and 6.5% (between 5.0% and 7.0% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of between €2.10 and €2.30.

Bernd Montag, CEO of Siemens Healthineers AG:

The Healthineers team has continued its successful growth trajectory, even relative to an excellent prior-year quarter. After an overall strong first half of the year, we are once again well on our way to achieving our targets for the financial year.

Source & Image Credit: Siemens Healthinears

Published on: Tue, 7 May 2024